Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic

Nenhuma Miniatura disponível
Citações na Scopus
Tipo de produção
Data de publicação
Título da Revista
ISSN da Revista
Título do Volume
HERRERA, Ana M. Mantilla
SHADID, Jamileh
PIGOTT, David M.
ABBAFATI, Cristiana
ADOLPH, Christopher
AMLAG, Joanne O.
ARAVKIN, Aleksandr Y.
LANCET, v.398, n.10312, p.1700-1712, 2021
Projetos de Pesquisa
Unidades Organizacionais
Background Before 2020, mental disorders were leading causes of the global health-related burden, with depressive and anxiety disorders being leading contributors to this burden. The emergence of the COVID-19 pandemic has created an environment where many determinants of poor mental health are exacerbated. The need for up-to-date information on the mental health impacts of COVID-19 in a way that informs health system responses is imperative. In this study, we aimed to quantify the impact of the COVID-19 pandemic on the prevalence and burden of major depressive disorder and anxiety disorders globally in 2020. Methods We conducted a systematic review of data reporting the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic and published between Jan 1, 2020, and Jan 29, 2021. We searched PubMed, Google Scholar, preprint servers, grey literature sources, and consulted experts. Eligible studies reported prevalence of depressive or anxiety disorders that were representative of the general population during the COVID-19 pandemic and had a pre-pandemic baseline. We used the assembled data in a meta-regression to estimate change in the prevalence of major depressive disorder and anxiety disorders between pre-pandemic and mid-pandemic (using periods as defined by each study) via COVID-19 impact indicators (human mobility, daily SARS-CoV-2 infection rate, and daily excess mortality rate). We then used this model to estimate the change from pre-pandemic prevalence (estimated using Disease Modelling Meta-Regression version 2.1 [known as DisMod-MR 2.1]) by age, sex, and location. We used final prevalence estimates and disability weights to estimate years lived with disability and disability-adjusted life-years (DALYs) for major depressive disorder and anxiety disorders. Findings We identified 5683 unique data sources, of which 48 met inclusion criteria (46 studies met criteria for major depressive disorder and 27 for anxiety disorders). Two COVID-19 impact indicators, specifically daily SARS-CoV-2 infection rates and reductions in human mobility, were associated with increased prevalence of major depressive disorder (regression coefficient [B] 0.9 [95% uncertainty interval 0.1 to 1.8; p=0.029] for human mobility, 18.1 [7.9 to 28.3; p=0.0005] for daily SARS-CoV-2 infection) and anxiety disorders (0.9 [0.1 to 1.7; p=0.022] and 13.8 [10.7 to 17.0; p<0.0001]. Females were affected more by the pandemic than males (B 0.1 [0.1 to 0.2; p=0.0001] for major depressive disorder, 0.1 [0.1 to 0.2; p=0.0001] for anxiety disorders) and younger age groups were more affected than older age groups (-0.007 [-0.009 to -0.006; p=0.0001] for major depressive disorder, -0.003 [-0.005 to -0.002; p=0.0001] for anxiety disorders). We estimated that the locations hit hardest by the pandemic in 2020, as measured with decreased human mobility and daily SARS-CoV-2 infection rate, had the greatest increases in prevalence of major depressive disorder and anxiety disorders. We estimated an additional 53.2 million (44.8 to 62.9) cases of major depressive disorder globally (an increase of 27.6% [25.1 to 30.3]) due to the COVID-19 pandemic, such that the total prevalence was 3152.9 cases (2722.5 to 3654.5) per 100 000 population. We also estimated an additional 76.2 million (64.3 to 90.6) cases of anxiety disorders globally (an increase of 25.6% [23.2 to 28.0]), such that the total prevalence was 4802.4 cases (4108.2 to 5588.6) per 100 000 population. Altogether, major depressive disorder caused 49.4 million (33.6 to 68.7) DALYs and anxiety disorders caused 44.5 million (30.2 to 62.5) DALYs globally in 2020. Interpretation This pandemic has created an increased urgency to strengthen mental health systems in most countries. Mitigation strategies could incorporate ways to promote mental wellbeing and target determinants of poor mental health and interventions to treat those with a mental disorder. Taking no action to address the burden of major depressive disorder and anxiety disorders should not be an option.
  1. Abbafati C, 2020, LANCET, V396, P1204
  2. American Psychiatric Association, 2000, DIAGN STAT MAN MENT, VIV, DOI [10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr, DOI 10.1176/DSM10.1176/APPI.BOOKS.9780890420249.DSM-IV-TR]
  3. Arenas-Arroyo E, 2021, J PUBLIC ECON, V194, DOI 10.1016/j.jpubeco.2020.104350
  4. Bell DNF, 2011, OXFORD REV ECON POL, V27, P241, DOI 10.1093/oxrep/grr011
  5. Burki T, 2020, LANCET INFECT DIS, V20, P904, DOI 10.1016/S1473-3099(20)30568-5
  6. Burstein R, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0064-y
  7. Campion J, 2020, LANCET PSYCHIAT, V7, P657, DOI 10.1016/S2215-0366(20)30240-6
  8. Clarke DM, 2009, MED J AUSTRALIA, V190, pS54
  9. Economou M, 2013, J AFFECT DISORDERS, V145, P308, DOI 10.1016/j.jad.2012.08.008
  10. Flaxman AD, 2015, An integrative metaregression framework for descriptive epidemiology
  11. Frasquilho D, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2720-y
  12. Heen M.S. J., 2014, COMP DIFFERENT ONLIN
  13. Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8
  14. Institute for Health Metrics and Evaluation, 2020, COVID 19 PROJ
  15. Jorm AF, 2017, WORLD PSYCHIATRY, V16, P90, DOI 10.1002/wps.20388
  16. Knudsen AKS, 2021, LANCET REG HEALTH-EU, V4, DOI 10.1016/j.lanepe.2021.100071
  17. Kola L, 2021, LANCET PSYCHIAT, V8, P535, DOI 10.1016/S2215-0366(21)00025-0
  18. Lavrakas PJ., 2008, BMJ, DOI [DOI 10.1136/BMJ.F6304, 10.1136/bmj.f6304]
  19. Lee S, 2010, J AFFECT DISORDERS, V126, P125, DOI 10.1016/j.jad.2010.03.007
  20. Levay KE, 2016, SAGE OPEN, V6, DOI 10.1177/2158244016636433
  21. Madianos M, 2011, SOC PSYCH PSYCH EPID, V46, P943, DOI 10.1007/s00127-010-0265-4
  22. Maulik PK, 2020, INT J MENT HEALTH SY, V14, DOI 10.1186/s13033-020-00393-4
  23. Moitra M, 2021, J PSYCHIATR RES, V137, P242, DOI 10.1016/j.jpsychires.2021.02.053
  24. Moreno C, 2020, LANCET PSYCHIAT, V7, P813, DOI 10.1016/S2215-0366(20)30307-2
  25. Mortier P, 2021, EPIDEMIOL PSYCH SCI, V30, DOI 10.1017/S2045796021000093
  26. Nichols E, 2019, LANCET NEUROL, V18, P88, DOI [10.1136/bmj.l94, 10.1016/S1474-4422(18)30403-4]
  27. Page M.J., 2021, BMJ-BRIT MED J, V372, pn160, DOI [DOI 10.1136/bmj.n71, DOI 10.1136/BMJ.N71, 10.1136/bmj.n160, DOI 10.1136/bmj.n160]
  28. Patel V, 2016, LANCET, V387, P1672, DOI 10.1016/S0140-6736(15)00390-6
  29. Piquero AR, 2021, J CRIM JUST, V74, DOI 10.1016/j.jcrimjus.2021.101806
  30. Pirkis J, 2021, LANCET PSYCHIAT, V8, P579, DOI 10.1016/S2215-0366(21)00091-2
  31. Reiner RC, 2021, NAT MED, V27, P94, DOI 10.1038/s41591-020-1132-9
  32. Solmi F, 2021, LANCET CHILD ADOLESC, V5, P316, DOI 10.1016/S2352-4642(21)00094-8
  33. Stevens GA, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002056, 10.1371/journal.pmed.1002116]
  34. Tanaka T, 2021, NAT HUM BEHAV, V5, P229, DOI 10.1038/s41562-020-01042-z
  35. Taquet M, 2021, LANCET PSYCHIAT, V8, P416, DOI 10.1016/S2215-0366(21)00084-5
  36. the United Nations, 2020, UN Policy Brief: The Impact of COVID-19 on Women 9 April
  37. Thornicroft G, 2007, LANCET, V370, P807, DOI 10.1016/S0140-6736(07)61392-0
  38. UNESCO, 2021, ED DISR REC
  39. Wenham C, 2020, NATURE, V583, P194, DOI 10.1038/d41586-020-02006-z
  40. WHO, 1992, ICD 10 CLASS MENT BE
  41. Winkler P, 2020, EPIDEMIOL PSYCH SCI, V29, DOI 10.1017/S2045796020000888
  42. Zheng P, 2021, J COMPUT GRAPH STAT, V30, P544, DOI [10.1080/10618600.2020.1868303, 10.1155/2021/5569464]